Section Arrow
EPIX.NASDAQ
- ESSA Pharma
Quotes are at least 15-min delayed:2025/07/20 13:08 EDT
Regular Hours
Last
 1.88
+0.01 (+0.53%)
Day High 
1.88 
Prev. Close
1.87 
1-M High
1.88 
Volume 
328.75K 
Bid
1.86
Ask
1.88
Day Low
1.86 
Open
1.87 
1-M Low
1.6606 
Market Cap 
82.91M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.78 
20-SMA 1.75 
50-SMA 1.72 
52-W High 7.88 
52-W Low 1.4 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.64/-0.68
Enterprise Value
83.12M
Balance Sheet
Book Value Per Share
2.56
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
NCNANuCana plc0.0477+0.0009+1.92%-- 
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Quotes are at least 15-min delayed:2025/07/20 13:08 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.